{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:12:51Z","timestamp":1789153971911,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chengdu Traditional Chinese Medicine University","award":["XJ2023009701"],"award-info":[{"award-number":["XJ2023009701"]}]},{"name":"Chengdu Traditional Chinese Medicine University","award":["JGJD202435"],"award-info":[{"award-number":["JGJD202435"]}]},{"name":"Deyang Science and Technology Bureau","award":["2024SZY003"],"award-info":[{"award-number":["2024SZY003"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Primary heavy and light chain amyloidosis (AHL) is extremely rare globally. This study aimed to report the first clinical treatment of AHL secondary diabetes. We also analyzed fasting blood glucose levels across various treatments. Finally, a reference was provided for treatment and laboratory indicators in AHL with secondary diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>The patient was treated in Department of Hematology in Deyang People\u2019s Hospital. He underwent treatment with daratumumab (DARA) + cyclophosphamide, bortezomib, and dexamethasone (CyBorD), autologous stem cell transplantation and bortezomib for AHL, alongside empagliflozin for blood glucose management. Clinical data and laboratory results were collected during phases of treatment and follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>This patient was a middle-aged man with 2 months of swelling in both lower limbs. Tests, including serum and urine analyses and a kidney biopsy, diagnosed him with AHL (IgA-\u03bb).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>He was diagnosed with diabetes after 4 courses of DARA + CyBorD. Then DARA was discontinued. CyBorD, autologous stem cell transplantation, and bortezomib were continued for AHL, alongside empagliflozin for blood glucose management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Finally, very good partial remission and effective control of blood sugar were obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Current study presented a case of AHL with secondary diabetes following treatment with DARA + CyBorD. For patients with high fasting blood glucose undergoing targeted therapy or chemotherapy, oral glucose tolerance test and glycosylated hemoglobin tests were necessary for the overall health. The difference between free light chain trend changed earlier than 24-hour urine protein, offering guidance for early AHL treatment and enhancing patient quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043859","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T19:00:30Z","timestamp":1755543630000},"page":"e43859","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin combined with bortezomib in the treatment of heavy and light chain amyloidosis with secondary diabetes: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Naidan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Medical Records, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiman","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-3498","authenticated-orcid":false,"given":"Chengliang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Deyang People\u2019s Hospital, Deyang, Sichuan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1016\/j.clml.2020.06.017","article-title":"How we manage systemic immunoglobulin heavy chain amyloidosis (AH Amyloidosis) and immunoglobulin heavy-and-light-chain amyloidosis (AH\/AL Amyloidosis).","volume":"20","author":"Chaulagain","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"101193","DOI":"10.1016\/j.diabet.2020.09.003","article-title":"Immune checkpoint inhibitors and diabetes: mechanisms and predictors.","volume":"47","author":"Youssef","year":"2021","journal-title":"Diabetes Metab"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.artd.2022.101076","article-title":"Dexamethasone is associated with a statistically significant increase in postoperative blood glucose levels following primary total knee arthroplasty.","volume":"19","author":"Volkmar","year":"2023","journal-title":"Arthroplast Today"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"e930733","DOI":"10.12659\/AJCR.930733","article-title":"Glycemic profile of intravenous dexamethasone-induced hyperglycemia using continuous glucose monitoring.","volume":"22","author":"Zhang","year":"2021","journal-title":"Am J Case Rep"},{"key":"R8-20260911","first-page":"617","article-title":"Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.","volume":"104","author":"Liu","year":"2025","journal-title":"Ann Hematol"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/10428194.2020.1849675","article-title":"Posttreatment dFLC less than 10 mg\/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.","volume":"62","author":"Shen","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamainternmed.2024.7381","article-title":"Effectiveness of empagliflozin vs dapagliflozin for kidney outcomes in type 2 diabetes.","volume":"185","author":"Bonnesen","year":"2025","journal-title":"JAMA Intern Med"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13506129.2025.2463678","article-title":"Supportive care for systemic amyloidosis: international society of amyloidosis (ISA) expert panel guidelines.","volume":"32","author":"Muchtar","year":"2025","journal-title":"Amyloid"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","article-title":"Empagliflozin: a review in type 2 diabetes.","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial.","volume":"40","author":"S\u00f8fteland","year":"2017","journal-title":"Diabetes Care"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1517\/14656566.2015.1114098","article-title":"Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.","volume":"16","author":"Triplitt","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials.","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:01:36Z","timestamp":1789153296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":15,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043859","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2025-03-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}